Related Experiment Video

Updated: Sep 29, 2026

Surgical Porcine Model of Chronic Myocardial Ischemia Treated by Exosome-laden Collagen Patch and Off-pump Coronary Artery Bypass Graft
05:25

Surgical Porcine Model of Chronic Myocardial Ischemia Treated by Exosome-laden Collagen Patch and Off-pump Coronary Artery Bypass Graft

Published on: September 15, 2023

A stratified approach to the treatment of a symptomatic myocardial bridge

Mardi Gomberg-Maitland1, Michael C Kim, Valentin Fuster

  • 1Department of Cardiology, The Cardiovascular Institute, Mount Sinai Medical Center, New York, New York 10029, USA.

Clinical Cardiology
|October 12, 2002
PubMed

Insights

Symptomatic myocardial bridges can necessitate intracoronary stenting. This case highlights in-stent restenosis as a complication, proposing a stratified treatment approach for myocardial bridges.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Cardiovascular Medicine

Background:

  • Myocardial bridges are congenital anomalies where a segment of coronary artery tunneled within the myocardium.
  • Symptomatic myocardial bridges can lead to angina, myocardial infarction, and arrhythmias.
  • Surgical or interventional treatments are considered for severe or refractory cases.

Observation:

  • A case of symptomatic myocardial bridge is presented.
  • The patient required intracoronary stenting for management.
  • In-stent restenosis developed as a complication post-stenting.

Findings:

  • Intracoronary stenting can be a treatment option for symptomatic myocardial bridges.
  • In-stent restenosis is a potential complication following stenting in myocardial bridges.
  • A stratified approach may guide the management of symptomatic myocardial bridges.

Implications:

  • This case underscores the importance of monitoring for and managing in-stent restenosis after coronary stenting in myocardial bridges.
  • The proposed stratified approach may offer a framework for optimizing treatment strategies.
  • Further research is warranted to evaluate long-term outcomes of various treatment modalities for myocardial bridges.

More Related Videos

3D Whole-heart Myocardial Tissue Analysis06:53

3D Whole-heart Myocardial Tissue Analysis

Published on: April 12, 2017

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...